These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 26080839)

  • 21. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M; Fulda S
    Cancer Lett; 2015 Apr; 360(1):1-9. PubMed ID: 25637161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
    Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
    Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
    Li H; Liu L; Chang H; Zou Z; Xing D
    Cell Death Dis; 2018 Jan; 9(2):137. PubMed ID: 29374168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
    Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R; Morchon E; Martinez-Argudo I; Serrano R
    Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity.
    Durrant DE; Das A; Dyer S; Tavallai S; Dent P; Kukreja RC
    Mol Pharmacol; 2015 Sep; 88(3):512-23. PubMed ID: 26101222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
    Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
    Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas.
    Lee M; Wiedemann T; Gross C; Leinhäuser I; Roncaroli F; Braren R; Pellegata NS
    Clin Cancer Res; 2015 Jul; 21(14):3204-15. PubMed ID: 25838390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
    Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
    Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.